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Background: Consistent delivery of medication to treat asthma and chronic obstructive pulmo-
nary disease (COPD) is critical for disease control. Dose tracking may eliminate the possibility
of sub-therapeutic dosing. This study evaluated the overall performance, including accuracy
and ruggedness, of themometasone furoate/formoterol (MF/F)metered-dose inhaler (MDI) with
an integrated numerical dose-countingmechanism in adolescent and adult subjects (aged12 y)
with persistent asthma or COPD.
Methods: In a phase III, open-label, single-arm, multicenter study, subjects demonstrating at
least 90% compliance with MF/F during the screening period received twice daily MF/F MDI
100/10 mg with the integrated dose counter for 4 weeks. Accuracy and ruggedness of the dose
counter were assessed by the overall discrepancy rate of subject-recorded actuations versus
subject-recordeddose counter readings. Discrepancy rates for Counterstrip, amanual counting
method, were evaluated for reference. Compliance and ergonomic safety were also assessed.
Results: The 233 subjects who used 90% of labeled actuations were included in the primary
analysis. Of 26,317 total actuations, 33 dose counter discrepancies occurred (rateZ 0.13/100
actuations), ofwhich 13were due to undercounting. In comparison, theCounterstrip discrepancy
rate was 10-fold higher (1.34/100 actuations). Compliance with medication use, Counterstrip
use, and e-diary recordings were all high (>98%). No new repetitive strain injuries or exacerba-
tions of preexisting ergonomic injuries of the finger, hand, or arm were reported.740 5540.
merck.com (C. Weinstein).
1 Elsevier Ltd. All rights reserved.
980 C. Weinstein et al.Conclusions: The MF/F MDI dose counter was accurate and rugged in subjects with asthma or
COPD.Nonew repetitive strain injuries or exacerbations of existing ergonomic injurieswere asso-
ciated with inhaler use.
Clinical trial registration number: ClinicalTrials.gov identifierZ NCT00604500
ª 2011 Elsevier Ltd. All rights reserved.Introduction
According to national and international asthma and chronic
obstructive pulmonary disease (COPD) guidelines, the main
goal of treatment is to maintain disease control, primarily
measured by the severity of symptoms, airflow obstruction,
and the frequency of exacerbations.1e3 In addition, these
treatment guidelines stress the importance of appropriate
and consistent medication delivery in asthma and COPD
management. Medication for controlling asthma and COPD
is principally delivered by pressurized metered-dose in-
halers (MDIs) or dry powder inhalers (DPIs) to allow for high
lung deposition with minimal systemic adverse effects.
Studies have shown that when correctly used, there are no
differences in clinical outcomes between MDIs and DPIs.4,5
However, when misused, both MDIs and DPIs contribute to
a decrease in asthma or COPD stability.6e8
Even when inhalers are well designed and used correctly,
consistent medication delivery (particularly with MDIs,
which require 2 inhalations per dose) may be limited by the
patient’s inability to recall if they have taken their full
prescribed dose. Such inconsistent asthma medication use
can have serious clinical implications by contributing to an
increased risk of exacerbations and poor outcomes.9e13
Another barrier to consistent and optimal therapeutic
delivery is the inability of patients to know when their
inhaler is empty.14 To help patients keep better track of their
dosing and promote consistent usage, manufacturers have
begun to incorporate dose counters into their inhalation
delivery devices. A reliable dose counter can help patients
track their medication use, determine when to replace their
inhaler, and prevent them from actuating their inhaler
beyond the labeled number of doses. In 2003, the US Food
and Drug Administration (FDA) released a guidance docu-
ment for industry on integrating dose counters into MDIs.
Although this guidance allows for both numerical counters
and dose indicators, including those that convey only end-of-
use information, the FDA recommends that all dose counter
mechanisms be evaluated for accuracy, ruggedness, and
ergonomics.15 For numerical countingmechanisms, accuracy
relates to the ability of the dose counter to decrement 1 unit
upon patient actuation. Ruggedness requires that the
counter performs accurately upon multiple actuations
(ie, over the life of the inhaler) under real-world handling
conditions. Ergonomics indicates that the integration of the
dose counter into theMDI delivery device is user-friendly and
does not present any safety or ergonomic handling issues.
Mometasone furoate/formoterol (MF/F) is a recently
developed inhaled corticosteroid (ICS) and long-acting
b2-agonist (LABA) combination delivered via a hydrofluoro-
alkane-pressurized MDI (Dulera, Merck & Co., Whitehouse
Station, NJ) that has been approved by the FDA for the
treatment of asthma. MF/F MDI is also currently under
investigation for the treatment of COPD.The primary objective of this study was to evaluate the
overall performance of the MF/F MDI with an integrated
numerical dose-counting mechanism in terms of accuracy
and ruggedness in adolescent and adult patients with asthma
or COPD. Other objectives were to assess subject adherence
and safety (including ergonomics). Accuracy and ruggedness
were assessed by determining the overall dose counter
discrepancy rate (comparison of subject-recordednumber of
actuations to subject-recorded dose counter readings),
quartile discrepancy rates (discrepancy changes over time),
discrepancy size (magnitude of discrepancy), and end-of-use
agreement (discrepancy at end of inhaler life). Dose counter
discrepancies were also compared with discrepancies obs-
erved with Counterstrip (a non-mechanical numerical
counter affixed to the MDI). Compliance was monitored
throughout the study to confirm the primary assessment
results. Ergonomics were assessed through inhaler usability
metrics and monitoring of repetitive strain injuries.
Methods
Study design
This was a phase III, open-label, single-arm, multicenter
study conducted in the United States. The study was con-
ducted in accordance with principles of Good Clinical
Practice and was approved by the appropriate institutional
review boards and regulatory agencies. Written informed
consent was obtained from all subjects. The study duration
was a maximum of 7 weeks and included 3 phases (Fig. 1).
Phase 1 was a familiarization period (lasting up to 1 week)
during which subjects were trained and became acquainted
with the use of a placebo MDI matching the MF/F MDI
without a dose counter, a Counterstrip, and an electronic
diary (e-diary). Subjects remained on their prescribed
asthma or COPD treatment during this phase. Also during
this phase, medical history (including history of repetitive
strain injury [RSI]) was taken and routine laboratory tests
were conducted to determine study eligibility. Phase 2 was
a 2-week screening period during which subjects dis-
continued their previously prescribed asthma or COPD
treatment and received MF/F MDI 100/10 mg without the
dose counter (administered as 2 inhalations of MF/F
50/5 mg) twice daily (BID) and approximately 12 h apart, to
confirm acceptable MDI dosing technique, stable asthma
control, and at least 90% compliance with use of the
e-diary, Counterstrip, and study medication. Subjects who
did not meet the 90% compliance cut-off were disconti-
nued, and the reasons for non-compliance (ie, e-diary,
Counterstrip, study medication, and/or MDI technique)
were evaluated (Table 1). RSI history was also reassessed
during this phase to confirm subject eligibility. Phase 3 was
a 4-week treatment period during which subjects received
MF/F MDI 100/10 mg (administered as 2 actuations of MF/F
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Figure 1 Study design. MDI Z metered-dose inhaler; MF/F Z mometasone furoate/formoterol.
Dose counter performance with the MF/F inhaler 98150/5 mg) BID with an integrated dose counter. During the
treatment period, subjects returned to the study center
weekly for evaluation of their MDI dosing technique; the
use of their study medication, e-diary, Counterstrip; and
their RSI assessment. At these weekly visits, the investiga-
tor recorded the number of actuations displayed on the
physical dose counter and the physical Counterstrip for the
purpose of comparing them to the number of subject-
recorded actuations in the e-diary and to the prescribed
number of actuations (Fig. 2).
Subjects
Subjects included in the study were 12 years of age, of
either sex and of any race,with at least a 12-month history of
persistent asthma or COPD. Additional inclusion criteria
required asthma subjects to have a forced expiratory volume
in 1 s (FEV1)70% andCOPD subjects to have a FEV150% and
a pre-bronchodilator FEV1/forced vital capacity ratio 0.70
at screening. Asthma subjects must have been using a low-
dose ICS with or without a LABA or medium-dose ICS without
a LABA for at least 12 weeks before screening and must have
had a stable dosing regimen for at least 2 weeks before
screening. There were no prestudy ICS requirements forTable 1 Non-compliance-related reasons for screen fail-
ures and discontinuations.a
Reason Screen Failures (n Z 56)
MDI technique 1
Non-compliance
e-diary 27
Study medication 12
Counterstrip usage 7
Otherb 28
Treatment period
discontinuations (n Z 11)
Non-compliance
e-diary 2
Study medication 2
Counterstrip usage 0
Otherb 7
a This table reflects a breakdown of the documented reasons
for non-compliance related to subject screen failures and
discontinuations. As subjects may have met more than one
reason for non-compliance, these numbers do not match those
for subject disposition.
b Documented reasons related to non-specific subject error or
non-compliance.COPD subjects. All subjects had to demonstrate 90%
compliance with e-diary completion, Counterstrip use, and
study medication use during the 2-week screening period
without the dose counter. Subjects were excluded if they
were unable to adequately use the MDI without the dose
counter or had a recent or current RSI or ergonomic injury
(eg, tenosynovitis, tendinosis) of the finger, hand, or arm
that, in the judgment of the investigator, could have pre-
vented the subject from effectively participating in the full
duration of the study.
Accuracy and ruggedness assessments
With each actuation, MDI use was recorded automatically by
the dose counter and manually on the Counterstrip (Fig. 3).
Actuations related to the initial priming of the MDI, per-
formed under the supervision of the study personnel, were
not included in the dose counter discrepancy evaluation.
Subjects were required to enter the dose counter and
Counterstrip values into their e-diary, both before and after
each of the 2 actuations that comprised 1 dose, during each
prescribed BID dosing session. Subjects also recorded
whether or not the actuation was inhaled and the actual
date/time of inhalation for comparison with the e-diary’s
automated date/time stamp. The e-diary prompted the
subject to contact the study center if the actuation was not
inhaled or if the dose counter or Counterstrip e-diary values
were not consistent with either the number of recorded
actuations or the number of prescribed actuations. ThereFigure 2 Integrated approach to identifying true dose
counter discrepancies.
Figure 3 Recording devices used. (A) MF/F MDI with inte-
grated dose counter and affixed Counterstrip and (B) e-diary
with integrated peak expiratory flow (PEF) meter.
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inhalationsmadeby the subject: (1) subjectswere permitted
to record nonprescribed actuations and/or inhalations asso-
ciated with inadvertent/accidental actuations or test sprays
(that may have occurred at any time) in a nonstandard
e-diary session and (2) study centers were permitted to use
an investigator mode to enter actuations and/or inhalations
that the subject reported but did not enter into the e-diary
(unrecorded actuations).
Compliance assessments
To support the primary study objective of evaluating dose
counter performance, subject compliance with MDI tech-
nique, use of medication, Counterstrip, and e-diary were
closely monitored. At each weekly visit, the subject demon-
strated his/her ability to use the MDI, Counterstrip, and
e-diary as directed. An e-diary report was printed which
contained a compliance score for study medication, Coun-
terstrip, and e-diary use based on the previous week. The
investigators were also instructed to carefully review the
subject’s e-diary recordings including an evaluation of: any
missing or incomplete e-diary sessions, extra e-diary sessions(ie, inadvertent actuations), incomplete dosing sessions
(ie, <2 inhalations), dose counter readings that did not
decrementby1unit peractuation,Counterstrip readings that
did not increment by 1 unit per actuation, subject’s last
e-diary dose counter and Counterstrip recordings in com-
parison with the investigator-observed actual dose counter
and actual Counterstrip readings, and subject’s total number
of actuations versus the prescribed number of actuations.
Study-specific electronic data collection tools were used by
the study center to document non-compliance with each of
these study procedures.
Ergonomic assessments
Inhaler usability assessments included an evaluation of
missing e-diary data, failed doses, and need for further
instruction on use of the MF/F MDI dose counter. The
quality and design of the MF/F MDI dose counter were also
assessed through separate subject satisfaction assessments
(manuscript submitted). Ergonomic safety was reported
separately from other adverse events before dispensing the
MF/F MDI dose counter and after using MF/F MDI dose
counter for up to 4 weeks and included an assessment of RSI
of the finger, hand, or arm.
Safety assessments
Safety assessments included rescue medication use, sym-
ptom scores, peak expiratory flow (PEF) measurements,
and adverse events. The e-diary/PEF meter was used to
monitor subject safety throughout the course of the study
as follows: (1) the spirometry component of the e-diary was
used to measure PEF twice daily during the prescribed BID
e-diary session; (2) use of rescue medication (short-acting
b2-agonist or oral corticosteroid) was captured in the
e-diary; (3) asthma or COPD symptoms were assessed
through subject responses to questionnaires captured in
the e-diary; and (4) the e-diary was programmed to alert
the subject if PEF fell below his/her established stability
limit, rescue medication use exceeded the amount allowed
by the study, or there were other signs of asthma or COPD
worsening. Adverse events were also monitored.
Accuracy and ruggedness analysis
The accuracy and ruggedness of the MF/F MDI dose counter
were primarily assessed by the discrepancy rate over the
life of the inhaler (120 labeled actuations) for subjects who
used at least 90% of the labeled number of actuations
during the treatment period (Completer Population). Dose
counter discrepancy rates were calculated as the differ-
ence between the subject-recorded number of actuations
versus the subject-recorded dose counter readings per 100
actuations. For comparative purposes, the dose counter
discrepancy rate was also computed for all subjects who
used the MF/F MDI dose counter, regardless of compliance
or duration of use (Treatment Period Population). Discrep-
ancies were classified as Undercounting (dose counter did
not count down upon actuation [spray, not count] or dose
counter counted upward without a known actuation [count
up, unknown spray]) or Overcounting (dose counter
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Figure 4 Subject disposition.
Dose counter performance with the MF/F inhaler 983counted down without an actuation [count, not spray] or
with an unknown spray [count, unknown spray]).
To fully characterize dose counter accuracy and rugged-
ness, quartile discrepancy rates (discrepancy rates between
weekly site visits), discrepancy size (magnitude of discrep-
ancy), and end-of-use agreement (discrepancy at end of
inhaler life) were also evaluated. For comparative purposes,
Counterstrip discrepancy rates were calculated as the
subject-recorded number of actuations versus the subject-
recorded Counterstrip readings per 100 actuations.
Dose counter accuracy check
A Dose Counter Accuracy Check (DCAC) was performed at
every scheduled visit to identify suspected dose counter
discrepancies.16 The DCAC is an algorithm that applied a pre-
defined set of criteria to the subject’s e-diary data accrued
since the last weekly visit to identify a suspected dose counter
discrepancy. Each time the DCAC was performed, it compared
the change in dose counter value with 3 other indices of
actuations: total recorded actuations, the Counterstrip, and
prescribed actuations. The DCAC indicated the possibility of
a true dose counter discrepancy and the need for further
investigation, including an in vitro analysis consisting of
a prespecified root cause analysis plan with visual, dimen-
sional, and functional testing of the MDI and its components.
Anomalies
The total error rate (anomaly rate) was estimated from the
e-diary count sequence for the purpose of comparison to
the dose counter discrepancy rate identified by the DCAC.
The dose counter anomaly rate was computed as the total
number of differences between the expected and actual
e-diary recorded dose counter values (ie, every actuation in
thee-diary that thedosecounter didnotdecrementby1unit).
Dose counter anomalies may arise from a true malfunction of
thedosecounter or subjecterror (readingordataentryerrors)
and subject non-compliance with recording actuations (not
recording actuations or recording actuations that were not
performed). The rate of subject error and non-compliance
with the dose counter was calculated by subtracting the dose
counter discrepancy rate fromthedosecounter anomaly rate.
This estimate of subject error/non-compliance rate was used
to validate the utility of the DCAC and its ability to discrimi-
nate between subject error/non-compliance and “true” dose
counter discrepancies. Calculation of the dose counter
subject error/non-compliance rate also allows for a direct
comparison to the Counterstrip discrepancy rate because, as
a non-mechanical counter, its count sequence differences are
due only to subject error or non-compliance. Documented
subject error or non-compliance was not included in the final
dose counter discrepancy calculations.
Statistics
The study was designed with a target sample size of 240
subjects. For this sample size, assuming a 1% discrepancy
rate, the 95% CI would be 0.885e1.115%. In addition,
approximately 25% of the subjects were to be 65 years or
older. For all assessments, only descriptive statistics were
performed. Based on the study objectives, there were noprespecified hypotheses andno formal comparisons between
treatment groups were conducted.
Results
Demographics and baseline characteristics
To ensure a thorough evaluation of the dose counter over
its intended lifespan, the clinical protocol stipulated that
the primary data analysis include subjects who used 90%
of the labeled actuations during the treatment period
(Completer Population). Of the 272 subjects who used the
MF/F MDI with dose counter (Treatment Period Population),
233 subjects were in the Completer Population (Fig. 4). In
the Completer Population, most of the subjects were white
women; 25% were 65 years of age and 81% had persistent
asthma (Table 2). Demographic characteristics of the
Treatment Period Population were comparable to those of
the Completer Population.
Dose counter discrepancies
Of the 26,317 actuations recorded by the Completer
Population, there were 33 dose counter discrepancies,
resulting in a dose counter discrepancy rate of 0.13 per
100 actuations (Table 3). When assessed by subject age,
the dose counter discrepancy rates were higher in
subjects <65 years of age compared with those 65 years
of age (0.14 vs 0.07, respectively; Table 3). Dose counter
Table 2 Demographic and baseline characteristics for the
Completer Population.a
Characteristic N Z 233
Age, y
Range 12e92
<65, n (%) 174 (75)
65, n (%) 59 (25)
Sex, n (%)
Women 156 (67)
Race, (%)
White 211 (91)
Disease, n (%)
Persistent asthma 189 (81)
Chronic obstructive pulmonary disease 44 (19)
a Subjects who took 90% of labeled actuations during the
treatment period.
984 C. Weinstein et al.discrepancies throughout the life of the inhaler were also
assessed by dividing the data into quartiles that reflected
each of the 4 weekly visits during the treatment period,
with the highest discrepancy rate observed in quartile 4
(0.20 per 100 actuations; Table 3). The discrepancy rate
for the Treatment Period Population was 0.14 per 100
actuations, indicating that subjects who did not complete
the study did not experience more dose counter
discrepancies.
Without applying the DCAC to filter out random count
sequence errors, 25% of the inhalers had a non-zero end-
of-use agreement. After removing documented subject
errors and non-compliance indicated by the DCAC, 92% of
the 233 MDIs used by the Completer Population had no
dose counter discrepancies, including a perfect end-of-use
agreement (ie, final dose counter reading was in agree-
ment with the total number of recorded actuations).
Analysis of the Treatment Period Population produced
similar results, with no dose counter discrepancies in 91%
of the inhalers.
Only 13 of the 33 dose counter discrepancies in the
Completer Population were due to undercounting, for
a rate of 0.05 per 100 actuations (Fig. 5). All of the
undercounts were attributed to a spray with no count.
When analyzed by the discrepancy size, 100% were 2 counts
or less, with all 13 undercounting discrepancies differing by
only 1 count. Of the 20 overcounting discrepancies (rate of
0.07 per 100 actuations), 14 were attributed to a count with
no spray (Fig. 5).Table 3 MF/F MDI dose counter discrepancy and anomaly rates
Quartile Discrepancy rate per 100 actuations
Total
N Z 233
Age < 65 y n Z 174 Age  65 y n Z
1 0.09 0.10 0.06
2 0.06 0.06 0.06
3 0.14 0.17 0.06
4 0.20 0.23 0.11
Overall 0.13 0.14 0.07
MF/F Z mometasone furoate/formoterol; MDI Z metered-dose inhalIn vitro analysis
At the end of the treatment period, inhalers were returned
for in vitro evaluation if a dose counter discrepancy was
suspected (ie, indicated by the DCAC) or there was any
evidence of damage.
Based on the results of this in vitro evaluation, as well as
the clinical evidence provided by the investigator, the
number of inhaler-related dose counter discrepancies was
compared with subject-related discrepancies (Table 4).
Counterstrip discrepancies
Out of 26,317 actuations in the Completer Population,
there were 353 Counterstrip discrepancies for a discrep-
ancy rate of 1.34 per 100 actuations (Table 5). When
assessed by age, the Counterstrip discrepancy rates were
higher in the population of subjects 65 years of age
compared with those <65 years of age (2.01 vs 1.11 per 100
actuations, respectively; Table 5). Most of the errors were
associated with reading the Counterstrip or entering the
Counterstrip reading into the e-diary.
Anomalies
Whereas subject error and non-compliance were theoreti-
cally eliminated by the DCAC to calculate true discrepancy
rates, the dose counter anomalies included both true dose
countermalfunctions and subject error in reading or entering
a value into the e-diary (overcount or undercount), and non-
compliance by failing to record an actuation (overcount) or
by recording an actuation that was not performed (under-
count). The overall rate of dose counter anomalies in the
Completer Population was 1.19 per 100 actuations (Table 3).
This indicates that the rate of subject error/non-compliance
is 9 times greater than the dose counter discrepancy rate,
and it demonstrates the effectiveness of the DCAC in
screening out subject error and non-compliance. The ano-
maly rate is similar to the Counterstrip discrepancy rate of
1.34 per 100 actuations, which, as stated previously, is
entirely due to subject error and non-compliance.
When assessed by age, more overall dose counter
anomalies occurred in subjects 65 years of age compared
with the younger subjects (rates of 1.78 vs 0.99 per 100
actuations, respectively; Table 3). The dose counter
anomaly rate was highest in the fourth quartile of the older
age group (2.06 per 100 actuations) and was much higheroverall, by age, and by quartile in the Completer Population.
Anomaly rate per 100 actuations
59 Total
N Z 233
Age < 65 y n Z 174 Age  65 y n Z 59
1.21 0.84 2.32
0.94 0.74 1.51
0.95 0.87 1.18
1.62 1.47 2.06
1.19 0.99 1.78
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Figure 5 Number of undercounting and overcounting dose counter discrepancies (discrepancy rate per 100 actuations).
Dose counter performance with the MF/F inhaler 985than in the corresponding quartile for the entire Completer
Population (1.62 per 100 actuations; Table 3).
Compliance
Compliance with study medication, Counterstrip use, and
e-diary recordings was high and few subjects discontinued
because of non-compliance (Table 1). Subjects in the
Completer Population recorded use of 98% of the prescribed
number of actuations. The most prevalent reason for non-
compliance with study medication was forgetting to take
the medication. In addition to high levels of subject com-
pliance with prescribed dosing, study medication was used
as directed (ie, 1 dose consisting of 2 inhalations taken with
proper MDI technique) 92% of the time it was evaluated by
the study center. High average compliance was also ob-
served in the Completer Population for the Counterstrip
(99.8%) and e-diary use (98.0%). Overall, compliance was
greater in the population of subjects 65 years compared
with younger subjects (Fig. 6).
Ergonomics and safety
Regarding ergonomics (inhaler usability), nearly all subjects
were able to use the MF/F MDI dose counter without ass-
istance. Approximately 90% (210 subjects) had no failed
doses. Only 4% (10 subjects) contacted the site by tele-
phone owing to an inability to use the inhaler as directed,
and none of these events required a clinic visit.Table 4 Number of subject-related or inhaler-related
discrepancies by quartile, age, and population.
Completer age, y Non-completer age, y Totals
<65 65 <65 65
Inhaler-related discrepancies
Q1 4 1 0 0 5
Q2 2 1 2 0 5
Q3 4 1 1 0 6
Q4 6 1 0 0 7
Totals 16 4 3 0 23
Subject-related discrepanciesa
Q1 1 0 1 0 2
Q2 1 0 4 0 5
Q3 3 0 1 0 4
Q4 7 1 0 0 8
Totals 12 1 6 0 19
a Reason Z undocumented actuation, subject error, count
when dropped, count when canister reassembled.In the Treatment Period Population (all 272 subjects),
safety evaluations revealed no new RSIs of the finger, hand,
or arm, and of the 6 subjects (2 asthma, 4 COPD) with
preexisting RSI symptoms, none reported an exacerbation.
Adverse event analysis determined treatment with MF/F
MDI 100 mg BID was safe and well tolerated in the study. The
most common adverse events were headache, oral candi-
diasis, upper respiratory tract infection, or oropharyngeal
pain. Each of these adverse events occurred in approxi-
mately 2% of subjects. Treatment-related adverse events
were reported in 4% of subjects, the most common being
oral candidiasis. Only 1 severe adverse event (dysphonia)
was considered treatment-related.
Discussion
The current study was designed to evaluate the accuracy,
ruggedness, and ergonomic safety of the MF/F MDI dose
counter, a feature that will enable patients to better track
medication use and determine when to replace the inhaler.
Dose counter accuracy and ruggedness were evaluated by
the rate of dose counter discrepancies between subject-
recorded actuations and actuations counted by the dose
counter throughout inhaler life. The MF/F MDI dose counter
proved to be reliable, tracking medication use with a low
rate of discrepancies (0.13 per 100 actuations), and most
(92%) of the MF/F MDI inhalers were without discrepancies.
Inhaler-related discrepancy rates throughout the life of
the inhaler were consistent as evidenced by data across the
quartiles. However, subject-induced discrepancies (ie,
dropping the inhaler, reinserting the canister, undocu-
mented actuations) were more prevalent in the later quar-
tiles for the younger (<65 y) subjects. These data reflect the
fact that the DCAC is more adept at removing random count
sequence errors due to subject error than it is at filtering
subject non-compliance. Therefore, the observed increase
in discrepancy rate over the life of the inhaler and betweenTable 5 Counterstrip discrepancy rates overall, by age,
and by quartile in the Completer Population.
Quartile Discrepancy rate per 100 actuations
Total
N Z 233
Age < 65 y,
n Z 174
Age  65 y,
n Z 59
1 1.12 0.86 1.89
2 0.81 0.53 1.63
3 1.14 0.93 1.74
4 2.22 2.05 2.72
Overall 1.34 1.11 2.01
Figure 6 Percentage completed e-diary sessions vs
prescribed e-diary sessions by age to illustrate overall e-diary
compliance, which includes twice-daily entries of dosing data
(ie, study medication use, Counterstrip use, and dose counter
recordings), peak expiratory flow data, and symptom data,
versus prescribed e-diary entries.
986 C. Weinstein et al.the twoage groupswas not considered to be a truedifference
in performance over the life of the inhaler.
Two other studies have evaluated the performance of
MDI numeric dose counters. The first study by Sheth et al
evaluated fluticasone propionate/salmeterol (FP/S) hydro-
fluoroalkane (HFA) MDI (Advair HFA; GlaxoSmithKline,
Research Triangle Park, NC) with an integrated dose
counter.17 The overall discrepancy rate with the FP/S MDI
was 0.94 per 100 actuations, and 58% of the subjects had no
discrepancy. The second study by Wasserman et al evalu-
ated albuterol HFA MDI (Ventolin HFA; GlaxoSmithKline,
Research Triangle Park, NC) with an integrated dose
counter.18 The overall discrepancy rate with the albuterol
MDI was 0.76 per 100 actuations, and 47% of the subjects
had no discrepancy. It should be noted that in the studies
by Wasserman et al18 and Sheth et al,17 subject error was
not excluded from their analyses, making the discrepancy
rates higher than if error was excluded as done in the
current study. When the dose counter discrepancy rate
from the current study (0.13 per 100 actuations) is sub-
tracted from the dose counter anomaly rate (1.19 per 100
actuations), the resultant discrepancy rate of 1.06 per 100
actuations is closer to the rates reported by Wasserman et
al and Sheth et al.17,18
A third study by Shah et al investigated the functionality
of a budesonide/formoterol (Symbicort; AstraZeneca,
Dunkerque, France) MDI with an indicator-type dose cou-
nter, rather than a direct numeric counter.19 Discrepancy
rates were not reported; therefore, a direct comparison
cannot be made to the dose counter discrepancy rates
reported here. However, Shah et al did report the differencebetween the final subject-recorded counter reading and the
total subject-recorded actuations at the end-of-use as
a mean difference with a 95% CI. This analysis is equivalent
to the end-of-use agreement in the current study (final dose
counter reading by investigator minus total number of
subject-recorded actuations). We performed a post-hoc
analysis to compare the Shah et al data to the Completer
Population results in the current study. In our Completer
Population, the average number of actuations was 112.9 (for
231 inhalers, 2 were not included because the dose counters
went beyond zero). This total number of actuations is closest
to one of the Shah et al study groups (group 2) in which the
mean number of actuations was 116.2 (for 86 inhalers). Shah
et al reported the mean difference to be 2.45 (95%
CI, 3.82 to 1.08) compared with 0.09 (95% CI, 0.06
to 0.23) in this study. The mean difference in this study was
closer to zero and after accounting for sample size differ-
ences, the variability between the final subject-recorded
counter reading was approximately 6-fold smaller (ie, ratio
of 95% CI ranges  ONZ (2.74  O86)/(0.29  O231)) in this
study than the Shah et al study. Unlike the MF/F numerical
counter which decrements 1 unit with each actuation, the
budesonide/formoterol counter does not provide a way for
the patient to see whether an individual actuation has been
performed. Therefore, it cannot be used by the patient to
monitor individual actuations/inhalations or daily dosing like
a numerical counter.
The MF/F MDI was designed to favor counting before
spraying in order to result in an overcount rather than an
undercount if the subject did not fully actuate the inhaler.
Of the 33 dose counter discrepancies in the current study,
only 13 (39%) were due to undercounting, meaning less
medication was available than the dose counter indicated.
The overall discrepancy rate for undercounting was low
(0.05 per 100 actuations) and is lower than that reported
for the FP/S MDI dose counter (0.33 per 100 actuations)17
and the albuterol MDI dose counter (0.13 per 100 actua-
tions).18 Undercounting is a less acceptable form of dose
counter error because of the potential for administration of
a sub-therapeutic dose.15 In vitro analysis demonstrated
that the undercounts were mostly associated with the MDI
spraying in advance of counting (data not shown).
The magnitude of undercounting is also important. All of
theMF/FMDIdosecounter discrepancieswerewithin 2 counts,
indicating that patient overestimation or underestimation of
remaining medication was no more than 1 dose, and all of the
undercountdiscrepancieswerewithin1count (ie,half adose).
In comparison, 87% and 88% of the FP/S MDI and albuterol MDI
dose counters, respectively, were within 2 counts; 5% and
3%, respectively, were off by more than 5 actuations.
There were several unique features of the current study
compared with previous dose counter performance studies.
The first unique feature was the incorporation of the fam-
iliarization period using a placebo without a dose counter,
which enabled subjects to become comfortable with the
inhaler before the start of the study. Possibly as a result of
this period, only 1 subject failed to enter the study because
of an inability to use the inhaler as directed. In addition,
there were no discontinuations attributed to an inability to
use the MF/F MDI with the dose counter during the study,
which supports the contention that the presence of the
dose counter does not alter the basic MDI technique.
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based on compliance with the e-diary and Counterstrip, in
addition to study medication. This allowed for exclusion of
subjects who were not compliant in recording their medi-
cation usage, which could affect discrepancy results.
The third unique feature of this study was the use of
the DCAC, which enabled subject error and non-compli-
ance to be segregated from dose counter discrepancies.16
Random errors were eliminated by incorporating site
observations of the actual dose counter and actual Coun-
terstrip values.
The fourth unique feature of the current study was that
subjects were instructed to record dose counter values
after each inhalation, not only after each full dose. This
facilitated the detection of random entry errors and hel-
ped to establish the reliability of the dose counter in
counting down only 1 number with every actuation.
Alternatively, the dose counter theoretically could have
stuck after the first actuation and counted down 2 numbers
after the second actuation, effectively disguising
a malfunction.
The fifth unique feature was the use of the Counterstrip
in conjunction with the dose counter. Unlike the dose
counter, the Counterstrip is non-mechanical. Therefore,
Counterstrip discrepancies are always a result of subject
error or non-compliance. The overall Counterstrip
discrepancy rate is analogous to the difference between
the dose counter discrepancy rate and the dose counter
anomaly rate (both are measures of subject error or non-
compliance). When the dose counter discrepancy rate is
subtracted from the anomaly rate (1.19  0.13Z 1.06), the
rate of dose counter subject error and non-compliance can
be estimated. Using this estimate, a relative increase of
26% more errors were made by subjects using the Coun-
terstrip than with the dose counter, and older subjects
(65 y) made more errors with the Counterstrip compared
with younger subjects. However, the older subjects were
more compliant with study medication and when compli-
ance differences were taken into consideration there were
no discernible differences in dose counter performance
between the older and younger subjects. The overall count
sequence differences (anomaly rate) between the dose
counter and Counterstrip was 0.93 per 100 actuations,
which is better than between either of the individual
counters and the subject-recorded actuations, suggesting
that both counting methods are more accurate than the
total recorded e-diary actuations.
The ergonomic safety of the inhaler was evaluated as
recommended by FDA guidance on the integration of dose
counters into MDI delivery devices.15 The addition of
a dose counter to an MDI should not impede a patient’s
ability to use the delivery device, although the integration
of the dose counter into the MDI delivery device requires
additional force to actuate the delivery device compared
with an MDI alone. RSI of the hands, wrists, and arms are
common in working adults, with prevalence estimated
from 5% to as high as 40% in some populations.20 There-
fore, it is important that the delivery device not exacer-
bate those conditions. In the current study, no new
exacerbations of RSI in the 6 subjects with prior injuries
were associated with the MF/F MDI-integrated dose
counter device.Conclusions
The MF/F MDI dose counter was demonstrated to be accu-
rate and rugged in a population of adolescents and adults
with asthma or COPD. Furthermore, the dose counter was
easy to use, and no new RSIs or exacerbations of existing
ergonomic injuries were associated with inhaler use.Acknowledgments
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